VORANIGO (Servier Laboratories (Aust) Pty Ltd)
Product name
VORANIGO
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
vorasidenib
Registration type
NCE/NBE
Indication
VORANIGO is indicated for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.